Given its role in regulation of neuroinflammatory and brain repair processes, the effect of depletion of CD38, a NAD glycohydrolase expressed by neurons, astrocytes and microglial cells, by daratumumab has been evaluated in the AD context (Guerreiro et al., 2020). This evidence concerns the gene CD38 and Alzheimer disease.